Cavendish has reiterated its buy rating on Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) following

The Medical - Generic Drugs industry gains from new launches, biosimilar momentum and portfolio shif

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t

Viatris Inc. (VTRS) Q2 2026 Earnings Call Transcript

On August 06, 2026, Viatris Inc (VTRS) shares fell 7.6%, closing at $16.29. Over the past year, the

Harrow Inc. (NASDAQ:HROW) on Thursday agreed to acquire Tyrvaya (varenicline solution) nasal spray 0

Viatris sells Tyrvaya to Harrow for up to $100 million, raises 2026 guidance after second-quarter ea

Viatris tops Q2 earnings and revenue estimates as Greater China sales surge 21%, helping lift result

Although the revenue and EPS for Viatris (VTRS) give a sense of how its business performed in the qu

Viatris (VTRS) came out with quarterly earnings of $0.69 per share, beating the Zacks Consensus Esti

Viatris (NASDAQ:VTRS) reported quarterly earnings of $0.69 per share which beat the analyst consensu

Viatris (NASDAQ:VTRS) raises FY2026 Adj EPS guidance from $2.33-$2.47 to $2.45-$2.49 vs $2.44 analys

Delivers Total Revenues of $3.8 Billion, Representing 5% Reported Growth Compared to Second Quarter

Beyond analysts' top-and-bottom-line estimates for Viatris (VTRS), evaluate projections for some of

VTRS readies Q2 results as growth in key markets and brands may offset manufacturing and pricing hea

PITTSBURGH, Aug. 4, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on August

Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earning

New Patch Will Provide Low-Dose Estrogen Combined Hormonal Contraceptive Option Approval Marks an Im

Trump plans tariffs of up to 200% on imported generic drugs after a two-year grace period aimed at e

Investors turn to dividend-yielding stocks during market turbulence. Benzinga's Analyst Stock Ra

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi

Investors interested in Medical Services stocks are likely familiar with Viatris (VTRS) and Danaher

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and

Healthcare has been an unloved corner of the market in 2026, but that neglect has created a rare set

Investors turn to dividend-yielding stocks in turbulent markets. Benzinga offers latest analyst rati

VR-205 Met Primary Endpoint and Key Secondary Endpoints and Was Well ToleratedVR-205 Efficacy and Sa

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Dru

U.S. officials discussed possible SSRI restrictions as RFK Jr. unveiled a broader push to reduce ant

JP Morgan analyst Chris Schott maintains Viatris (NASDAQ:VTRS) with a Neutral and raises the pric

Truist Securities analyst Srikripa Devarakonda maintains Viatris (NASDAQ:VTRS) with a Buy and rai

Health officials explored restricting specific antidepressants among SSRI drugs-sources

Viatris (NASDAQ:VTRS) affirms FY2026 Adj EPS guidance from $2.33-$2.47 to $2.33-$2.47 vs $2.44 analy

Viatris (NASDAQ:VTRS) reported quarterly earnings of $0.59 per share which beat the analyst consensu

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Theodora "Doretta

https://www.fda.gov/news-events/press-announcements/fda-takes-step-forward-testosterone-therapy-men

Investors turn to high-yielding dividend stocks in turbulent markets. Benzinga readers can check ana

Investors turn to dividend-yielding stocks in turbulent markets. Benzinga readers can check analyst

Barclays analyst Glen Santangelo maintains Viatris (NASDAQ:VTRS) with a Overweight and raises the

Collaboration expands access to trusted therapies with discounted cash prices for leading brands inc

Viatris (NASDAQ:VTRS) is looking for FY2026 Adj EPS of $2.33-$2.47 vs $2.49 analyst estimate. sees s

Viatris (NASDAQ:VTRS) reported quarterly earnings of $0.57 per share which beat the analyst consensu

FDA PDUFA Goal Date Set for October 17, 2026PITTSBURGH, Feb. 25, 2026 /PRNewswire/ -- Viatris Inc. (

Piper Sandler analyst David Amsellem maintains Viatris (NASDAQ:VTRS) with a Neutral and raises th

Builds on Viatris' Scientific Leadership and Commercial Legacy in Cardiovascular DiseasesPITTSBU

Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that the Company will prese